Abstract
Bromocriptine, a preferential D2 receptor agonist, was administered to six human narcoleptic patients during a double-blind, cross-over study. Laboratory sessions consisted of two all-night polysomnographic recordings and three daytime tests of vigilance: the Analogue Vigilance Scale (AVS), the Maintenance of Wakefulness Test (MWT), and the Four-Choice Reaction Time Test (FCRTT). No change in nocturnal sleep organization, daytime somnolence, or psychomotor performance was observed during bromocriptine administration. Periodic limb movements in sleep (PLMS) were significantly reduced during bromocriptine condition. These results suggest that D2 receptors are unlikely to play a major role in the physiopathology of human narcolepsy, and support the hypothesis that dopaminergic mechanisms are involved in PLMS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
